This is a ready-to-use analytical method validation summary report. It is the artifact a reviewer or inspector reads, so it stands or falls on whether an independent reader can reconstruct what was done and agree with the conclusion. Replace every <<FILL: ...>> placeholder, reference the approved protocol, and route through Quality Assurance approval. A worked filled specimen follows. This is general educational content to adapt, not regulatory advice; confirm each reference against the current source.
Document control header
| Field | Entry |
|---|---|
| Document title | Validation Summary Report for <<FILL: method name>> |
| Report number | <<FILL: RPT-ID, e.g. VAL-QC-0142-R>> |
| Version | <<FILL: version>> |
| Protocol reference | <<FILL: protocol number and version>> |
| Method reference | <<FILL: test method number and version>> |
| Product / analyte | <<FILL: product, dosage form, analyte>> |
| Effective date | <<FILL: date>> |
1. Purpose
To summarize the results of the validation performed under protocol <<FILL: protocol number>> and to state whether method <<FILL: method number>> is validated for its intended use: <<FILL: assay and related substances of the product>>. This report presents each characteristic’s result against the acceptance criterion that was fixed in the approved protocol before data were generated.
2. Scope of the validation
The following characteristics were evaluated, with the rationale for any not studied. The method was classified as a <<FILL: quantitative assay and impurity>> method, which sets the required characteristics per ICH Q2(R2).
| Characteristic | Studied? | Rationale if not studied |
|---|---|---|
| Specificity | <<FILL: Yes>> | |
| Accuracy | <<FILL: Yes>> | |
| Repeatability | <<FILL: Yes>> | |
| Intermediate precision | <<FILL: Yes>> | |
| Linearity and range | <<FILL: Yes>> | |
| LOQ / LOD (impurities) | <<FILL: Yes>> | |
| Solution stability | <<FILL: Yes>> | |
| Filter validation | <<FILL: Yes>> | |
| Robustness | <<FILL: Yes>> | |
| Reproducibility | <<FILL: No>> | <<FILL: single-site validation; addressed by transfer>> |
3. Results against acceptance criteria
Each row states the pre-defined criterion, the observed result, and the pass or fail call. This table is the core of the report; a reviewer reads it first.
| Characteristic | Acceptance criterion (from protocol) | Result | Pass/Fail |
|---|---|---|---|
| Specificity | No interference at analyte/impurity RT; peak purity above <<FILL: 0.99>>; mass balance within <<FILL: 5>>% | <<FILL>> | <<FILL>> |
| Accuracy (assay) | Mean recovery <<FILL: 98.0-102.0>>%, RSD not more than <<FILL: 2.0>>% | <<FILL>> | <<FILL>> |
| Accuracy (impurities) | Recovery <<FILL: 90-110>>% near limit | <<FILL>> | <<FILL>> |
| Repeatability | RSD not more than <<FILL: 2.0>>% (n=6) | <<FILL>> | <<FILL>> |
| Intermediate precision | Pooled RSD not more than <<FILL: 2.0>>% | <<FILL>> | <<FILL>> |
| Linearity | r not less than <<FILL: 0.999>>, random residuals | <<FILL>> | <<FILL>> |
| Range | Accurate, precise, linear across <<FILL: range>> | <<FILL>> | <<FILL>> |
| LOQ (impurities) | Confirmed, recovery <<FILL: 80-120>>%, RSD not more than <<FILL: 10>>%, below reporting threshold | <<FILL>> | <<FILL>> |
| Solution stability | Within <<FILL: 2.0>>% of fresh over the use period | <<FILL>> | <<FILL>> |
| Filter validation | Filtered within <<FILL: 2.0>>% of unfiltered | <<FILL>> | <<FILL>> |
| Robustness | Suitability and result hold across studied variations | <<FILL>> | <<FILL>> |
4. Data references
Point to where the raw data and calculations live, so the conclusion is reconstructable.
| Characteristic | Raw data / chromatogram reference | Calculation reference |
|---|---|---|
<<FILL: characteristic>> | <<FILL: sequence / notebook / CDS project>> | <<FILL: worksheet / report ID>> |
5. Deviations
List every protocol deviation, its cause, and its assessed impact on the validation conclusion. A validation with one well-explained deviation reads as credible; a suspiciously perfect validation with none across dozens of runs invites a closer look.
| Deviation ID | Description | Cause | Impact on conclusion |
|---|---|---|---|
<<FILL: none, or ID>> | <<FILL>> | <<FILL>> | <<FILL: no impact / explained>> |
6. Conclusion
Based on the results above, method <<FILL: method number>> <<FILL: is / is not>> validated for its intended use, <<FILL: assay and related substances of the product>>, over the range <<FILL: range>>. The established method controls carried forward into routine use are: system suitability criteria <<FILL: summary>>, solution use period <<FILL: hours>>, filter and discard volume <<FILL: detail>>, and constrained parameters from robustness <<FILL: detail>>. Any characteristic that failed, and the disposition, is stated here explicitly rather than omitted.
7. Regulatory placement
This report is referenced in the analytical procedure control documentation and, where the method supports a submission, in CTD Module 3 under the analytical procedures and validation sections (3.2.S.4.3 for the drug substance, 3.2.P.5.3 for the drug product). It is retained in the laboratory records per 21 CFR 211.194 and the records retention schedule, and is retrievable for inspection.
8. References
ICH Q2(R2), Validation of Analytical Procedures. ICH Q14, Analytical Procedure Development. 21 CFR 211.165(e), 211.194(a)(2). The approved validation protocol
<<FILL: number>>.
9. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (method owner) | <<FILL>> | ||
| Reviewer (QC / statistician) | <<FILL>> | ||
| Approver (Quality Assurance) | <<FILL>> |
10. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL: date>> | <<FILL: author>> | Initial issue. |
Filled specimen
The following shows the results table (section 3) completed for an illustrative tablet assay and related-substances method, so you can see the level of detail expected. Numbers are illustrative.
Method: TM-QC-0142, reverse-phase HPLC assay and related substances of Compound X tablets. Protocol: VAL-QC-0142 v1.0.
| Characteristic | Acceptance criterion | Result | Pass/Fail |
|---|---|---|---|
| Specificity | No interference; peak purity above 0.99; mass balance 95-105% | No interference; purity 0.999; mass balance 98.4% | Pass |
| Accuracy (assay) | Mean 98.0-102.0%, RSD not more than 2.0% | 99.8%, RSD 0.9% | Pass |
| Accuracy (impurity B) | Recovery 90-110% near 0.20% limit | 97.5% at limit | Pass |
| Repeatability | RSD not more than 2.0% (n=6) | 0.7% | Pass |
| Intermediate precision | Pooled RSD not more than 2.0% | 1.1% | Pass |
| Linearity | r not less than 0.999, random residuals | r = 0.9997, residuals random | Pass |
| Range | Accurate, precise, linear 50-150% | Demonstrated | Pass |
| LOQ (impurities) | Confirmed, recovery 80-120%, RSD not more than 10%, below 0.10% threshold | LOQ 0.05%, recovery 96%, RSD 6% | Pass |
| Solution stability | Within 2.0% of fresh over use period | Stable to 24 h (97.8% at 48 h, fails) | Pass, use period 24 h |
| Filter validation | Filtered within 2.0% of unfiltered | 99.7% after 2 mL discard | Pass |
| Robustness | Suitability and result hold across variations | Held; flow sensitivity constrained in method | Pass |
Conclusion (specimen): Method TM-QC-0142 is validated for assay and related substances of Compound X tablets over 50 to 150 percent of label claim. Carried-forward controls: solution use period 24 hours, 2 mL filter discard, flow rate constrained to plus or minus 5 percent in the method and reflected in system suitability. One deviation (a mis-set autosampler temperature on the first solution stability run, repeated correctly) had no impact on the conclusion.
Common inspection findings this report prevents
- Results reported without the pre-defined acceptance criterion beside them, so a reader cannot tell what “pass” was measured against.
- A conclusion of “validated” with a characteristic that quietly failed and was omitted.
- No reference to where the raw data live, so the conclusion cannot be reconstructed.
- Deviations dropped without an impact assessment.
- The report not retrievable, or missing the Quality Assurance approval that makes the conclusion official.
How to adapt this report
- Set your report and protocol numbers, and reference the approved protocol so the criteria trace back to their pre-approved source.
- Copy each acceptance criterion verbatim from the protocol into section 3; the report must not restate criteria differently from what was approved.
- State the carried-forward method controls (use period, filter discard, constrained parameters) explicitly in the conclusion, because these are what routine QC will rely on.
- List every deviation and its impact; do not present a validation with no deviations unless that is genuinely true.
- Confirm the CTD placement and the retention requirement against your submission plan and records schedule.